Month: September 2026

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Eleco Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	25/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p Ordinary Shares
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	1,154,470	1.36%
(2)   Cash-settled derivatives:
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,154,470	1.36%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
1p Ordinary Shares	Sale	840	229.512p

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
1p Ordinary Shares

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:	28/09/2026
Contact name:	Callum Ridley – Compliance Department
Telephone number:	0151 243 7037

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

November 17 FDA Meeting Set to Discuss Dosing and Trial Size for Second Drug in Pipeline

DENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is putting another major date on the biotech calendar: November 17, 2026, when the company is scheduled to meet with the U.S. Food and Drug Administration for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.

The meeting could become an important inflection point for a company that has rapidly assembled a string of clinical, regulatory and Wall Street catalysts.

NeOnc says it plans to seek FDA feedback on NEO212’s proposed patient population, trial design, endpoints, dose selection and the evidence that could ultimately support a marketing application. The company also intends to discuss a potential registrational strategy and whether a proposed Phase 2 design could potentially support an accelerated-approval pathway; marking a meaningful transition from dose-finding toward the next stage of clinical development.

NEO212 enters that meeting with some intriguing, though still preliminary, human data.

During Phase 1, dose escalation reached the protocol-defined maximum tolerated dose at 810 mg, after which the recommended Phase 2 dose was established at 610 mg. The company has highlighted a patient with recurrent IDH1 wild-type, MGMT-methylated glioblastoma who experienced an approximately 60% tumor reduction and 21 months of disease control. Another heavily pretreated patient with lung cancer metastatic to the brain experienced stable disease for approximately 16 months. These are individual patient observations, not proof of efficacy, and larger trials will have to determine whether the results can be replicated.

NeOnc CEO Amir Heshmatpour put the immediate objective plainly: “This meeting will help us understand FDA’s feedback on the population, study design and endpoints for the next stage of development.”

The NEO212 catalyst arrives as the broader NeOnc story is also attracting Wall Street attention. Roth Capital recently initiated coverage of NeOnc with a $20 price target, with analyst Jonathan Aschoff reportedly anticipating potential pivotal-trial starts by the end of 2026.

NeOnc is now advancing two potential therapies in its CNS cancer pipeline, giving investors more than one clinical catalyst to watch. Its lead program, NEO100, recently generated topline Phase 2a data in recurrent IDH1-mutant high-grade glioma, with the company reporting six-month progression-free survival of 48.9% versus a prespecified 20% benchmark and median overall survival of 26.09 months. NeOnc said it plans to engage with the FDA regarding a potential registrational pathway.

The parallel development tracks could give NeOnc multiple potential catalysts heading into 2027. Roth Capital’s research indicates Aschoff expects an FDA Type B End-of-Phase 2 meeting for NEO100 in October and sees potential pivotal-trial starts before the end of 2026.

Meanwhile, NeOnc has raised capital from institutional investors, including a September registered direct offering priced at $4.20 per share and accompanying warrants. Company insiders have also been active buyers: SEC filings show recent open-market purchases by executives including Heshmatpour and Thomas C. Chen.

That backdrop makes November 17 particularly interesting. NTHI is approaching the FDA with a defined Phase 2 dose, early signals of clinical activity and a stated ambition to develop NEO212 across difficult-to-treat CNS cancers.

If the agency provides a workable path forward on population, endpoints and study design, NEO212 could emerge from the meeting with a substantially clearer development roadmap.

For NTHI shareholders, November 17 is therefore less about expecting an approval and more about watching whether the FDA conversation turns NEO212 from an intriguing clinical program into a more clearly defined late-stage development story.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

Bagsværd, Denmark, 28 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 21 September, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	19,415,000		5,829,922,946
21 September 2026	250,000	267.41	66,853,084
22 September 2026	250,000	258.30	64,575,341
23 September 2026	220,000	256.17	56,357,077
24 September 2026	240,000	250.42	60,101,974
25 September 2026	245,000	253.19	62,031,620
Accumulated under the programme	20,620,000		6,139,842,042

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 49,419,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 25 September 2026, Novo Nordisk has since 4 February 2026 repurchased a total 35,379,179 B shares at an average share price of DKK 280.95 per B share equal to a transaction value of DKK 9,939,842,031.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Nordisk Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com
Novo Nordisk Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com	Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com	Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com

Company announcement No 58 / 2026

Attachments

• CA260928_Safe Harbour
• CA260928_Safe harbour transaction details

Proposed Cash Acquisition Expands Treasure Global into AI-Enabled Smart Utility Infrastructure

KUALA LUMPUR, Malaysia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a Southeast Asia–anchored technology company focused on AI-powered enterprise solutions and digital transformation, today announced that it has signed a non-binding memorandum of understanding (“MOU”) with Mestiz Holding Berhad (“MHB”) for the proposed US$38 million cash acquisition of a 51% controlling interest in Mestiz Century Logic Sdn Bhd (“MCL”), a Malaysia-based provider of cloud-based smart water metering technology and digital water management solutions.

Under the MOU, MHB has granted Treasure Global a 120-day exclusivity period to conduct due diligence on MCL and negotiate the terms of a definitive agreement. Completion of the proposed acquisition remains subject to the execution of a definitive agreement and customary closing conditions, including satisfactory completion of due diligence and receipt of required regulatory and board approvals.

MCL specializes in smart water metering solutions powered by cloud computing and Internet of Things (“IoT”) technology. Its smart meters are designed to deliver up to four times the accuracy of conventional mechanical meters, while providing enhanced durability and digital connectivity.

MCL’s smart metering platform further integrates artificial intelligence to support real-time consumption monitoring, remote meter reading, leak detection and predictive maintenance, enabling utilities to improve operational visibility and transition toward more intelligent, data-driven water management.

“Smart water metering represents a significant diversification opportunity for Treasure Global,” said Sam Teo, Acting Chief Executive Officer of Treasure Global. “MCL’s cloud-based, IoT and AI-enabled technology addresses a growing need among utilities to modernize aging water infrastructure, improve billing accuracy and reduce water loss. We believe intelligent metering, real-time data and predictive analytics can create meaningful operational value while supporting more efficient and data-driven water management.”

The proposed acquisition comes amid continued global growth in smart water infrastructure. According to Fortune Business Insights, the global smart water meter market is estimated at approximately US$6.02 billion in 2026 and is projected to reach approximately US$14.74 billion by 2034, representing a compound annual growth rate of approximately 11.85% over the forecast period.

If completed, the proposed acquisition would mark Treasure Global’s entry into the smart utility infrastructure sector, expanding the Company’s technology portfolio beyond digital payments and enterprise AI. The transaction would provide Treasure Global with exposure to a growing smart-metering market while supporting its strategy of building diversified, technology-driven revenue streams and long-term shareholder value.

About Treasure Global:
Treasure Global is a Malaysia-based technology solutions provider specializing in innovative platforms that drive digital transformation in retail and services. The Company’s flagship product is the ZCITY Super App, which integrates e-payment solutions with customer loyalty rewards to create a seamless online-to-offline user experience. As of March 31, 2026, ZCITY has attracted 2.71 million registered users, positioning Treasure Global as a key player in Malaysia’s digital economy. Treasure Global continuously leverages cutting-edge technologies, including artificial intelligence and data analytics, to enhance its platform’s capabilities across e-commerce, fintech, and other verticals.

Visit treasureglobal.org for more information.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company’s current expectations, assumptions, and projections about future events and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking statements typically include terminology such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” or similar expressions.

Factors that could cause actual results to differ materially include, without limitation, the parties’ ability to negotiate and execute a definitive agreement; satisfactory completion of due diligence; completion of the proposed acquisition; the Company’s ability to integrate MCL and realize anticipated strategic benefits; adoption and performance of MCL’s smart water metering technology; customer and utility demand; regulatory and procurement requirements; technology performance; cybersecurity and data privacy risks; competition; and changes in economic, infrastructure and market conditions.

The forward-looking statements in this press release speak only as of the date hereof. The Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

CONTACT
Investor and media contact:
Investor Relations Team
Treasure Global
ir_us@treasureglobal.org

Investment increases production capacity, supports booming consumer demand and reinforces Wisconsin’s leadership in dairy biosolutions

WEST ALLIS, Wis., Sept. 28, 2026 (GLOBE NEWSWIRE) — Novonesis, a global leader in biosolutions, announced the completion of a major expansion at its West Allis, Wisconsin production facility. The investment increases the company’s North American production capacity for dairy cultures, boosting fermentation capacity by approximately 66% and packaging capacity by 17%, while establishing West Allis as one of the world’s largest lactobacillus production facilities. The additional capacity will allow Novonesis to help customers keep pace with booming consumer demand for more nutritious foods without compromising taste, texture or quality, while reinforcing Wisconsin’s role as a leader in dairy manufacturing and innovation. 

“For nearly a century, West Allis has played an important role in helping advance dairy innovation,” said Theis Bacher, Senior Vice President, Food & Beverage, Novonesis North America. “Today, it serves as our North American center of excellence for food cultures. This expansion builds on that legacy, strengthening our ability to continue delivering the biosolutions our customers rely on while investing in the people, manufacturing capabilities and technology that will help shape the future of dairy. By enabling dairy manufacturers to produce nutritious, high-quality foods more efficiently and sustainably, we’re helping advance healthier living through biology.” 

“This investment is also a commitment to the West Allis community, reinforcing our dedication to providing high-quality, high-performing cultures to customers in Wisconsin and around the world,” said Anders Lund, Chief Operating Officer and Executive Vice President, Novonesis. “As ‘America’s Dairyland,’ Wisconsin takes great pride in its dairy heritage, and we are proud to be a leader in culture ingredients that support dairies and food manufacturers from farm to fork.” 

While the current expansion adds new jobs and significant production capacity, the site layout allows for additional growth over time by leveraging existing infrastructure along with automation and robotics. The project also incorporates energy-efficient equipment, water reuse, and waste heat recovery to reduce the environmental footprint of operations. Together, these enhancements expand Novonesis’ ability to produce the biosolutions food manufacturers rely on every day, helping customers improve how food is produced while supporting a more efficient, resilient bioeconomy. 

From the cultures used to make cheese and yogurt to innovations that help manufacturers improve product quality, reduce waste and operate more efficiently, Novonesis’ biosolutions help make nutritious dairy foods more accessible while supporting a more sustainable food system and advancing healthier lives on a healthier planet. 

“Wisconsin’s dairy leadership has always been built on the combination of tradition and innovation,” said John Umhoefer, executive director of the Wisconsin Cheese Makers Association. “Investments in advanced dairy manufacturing capabilities help strengthen the infrastructure our cheesemakers rely on, support skilled jobs and reinforce Wisconsin’s ability to remain at the forefront of dairy production. Novonesis’ continued investment in West Allis is another example of the innovation happening across our state’s dairy industry.” 

The West Allis site opened in 1929 and has long been part of Wisconsin’s dairy industry. Today, the facility employs 360 people and supplies cultures to dairy manufacturers across North America. The completion of the expansion marks another milestone in the site’s nearly century-long history of supporting dairy innovation and manufacturing.  

Novonesis celebrated the completion of the expansion with a ribbon-cutting ceremony attended by customers, employees, community leaders and industry partners.  Guests toured the expanded production facility and customer experience center, highlighting the technologies and capabilities that will support the next generation of dairy manufacturing. 

About Novonesis 

Novonesis is a global biosolutions company leading the era of biosolutions. By leveraging the power of microbiology with science, Novonesis transforms the way the world produces, consumes, and lives. Across more than 30 industries, Novonesis biosolutions are already creating value for thousands of customers while benefiting the planet. With more than 11,000 employees worldwide, Novonesis partners with businesses and communities to better our world with biology. 

Attachments

• West Allis Ribbon Cutting
• West Allis Ribbon Cutting

CONTACT: Kathy Humphrey
Novonesis
19193397110
Khp@novonesis.com

• Expansion benefits families, remote work, gaming, streaming, agriculture, telehealth
• In celebration, Kinetic to host free community festivities Sept. 28 – Oct. 5

CHARLOTTE, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) — Kinetic, the leading residential and business insurgent fiber internet provider, announced today that it increased its fiber network in the greater Concord area by nearly 23% in the last year.

Kinetic added more than 7,800 new fiber locations in the community, surpassing a major milestone of more than 38,000 homes passed. This expansion is fully funded by Kinetic and highlights the company’s commitment to this community and is a signal of future growth and opportunity across the region.

“Concord is a key market for Kinetic and an important link in the region’s growing technology corridor,” said Stacy Hale, Kinetic’s state operations president. “In honor of surpassing this milestone, it’s time that we celebrate. And to the residents of this area, know that we’re not done yet; we’ll continue adding more fiber locations and will remain a long-term partner to this community.”

Fast Forward: Concord — a Free Community Celebration
To celebrate this milestone, Kinetic will host a week of free events for the community.

Planned week highlights

• Tuesday, Sept. 29: Kinetic employees will volunteer at the Sonshine Backpack Ministry, a nonprofit program that provides weekly food bags to school aged children that face food insecurities.
• Thursday, Oct. 1: Kinetic will host a free technology, internet and security course from 10:30 – 11:15 a.m. at the Kannapolis VFW Post 8989 for those who need a more hands-on experience with tech.  
• Friday, Oct. 2: Concord Fiber Night Lights, where Kinetic will give away swag items at the Central Cabarrus vs Cox Mills high school football game starting at 7 p.m. While supplies last.
• Saturday, Oct. 3: Kinetic will have a booth at the Concord International Festival in Downtown Concord from noon to 6 p.m. Stop by for family fun and free swag items.

Why Kinetic’s fiber infrastructure matters to North Carolina
Fiber is the best technology for the long-term success of Concord’s communications needs. Research shows that fiber-connected communities experience 213% higher business growth, 10% higher self-employment and a potential 14-17% increase in home values. Fiber is also significantly more sustainable than copper and uses up to 95% less energy per gigabit. It requires less maintenance over time, which reduces environmental impact and community disruption.

As a long-term partner to the Concord community, Kinetic Is committed to delivering on its promise to provide fast, reliable, future-proof connectivity that helps local economic growth, education, telehealth, and small business competitiveness. This investment underscores the company’s dedication to providing the communities it serves—the same communities its employees also live and work in—with sustained value both now and for years to come.

Kinetic, which was also named CNET’s Best Rural Fiber Internet Provider in 2026, is rooted in North Carolina and is proud to serve its communities beyond internet connectivity. Kinetic’s fiber expansion milestone in Concord follows the company recently reaching 2 million homes passed with fiber internet across its 18-state footprint.

Residents who want to check fiber availability or construction updates can call 1- 877-90-FIBER (877-903-4237) or visit www.gokinetic.com.

About Kinetic: Named the 2026 Telecommunications Company of the Year (Stevie GOLD/American Business Awards), Kinetic is a business unit of Uniti (NASDAQ: UNIT), and is a premier insurgent provider of multi-gigabit fiber internet, whole-home Wi-Fi, internet security, and voice services in 1,400 markets across 18 states in the Southwestern, Southeastern, Midwestern, and Northeastern U.S. Additional information is available at gokinetic.com.

Media Contact
Victoria Carman
uniti.kinetic.pr@uniti.com

Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study

Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026

FDA alignment provides potential path to accelerated approval based on objective response rate and full approval based on progression-free survival

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech^® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced continued clinical and operational progress in REO 033, its randomized study evaluating pelareorep in second-line RAS-mutant, microsatellite-stable (“MSS”) metastatic colorectal cancer (“mCRC”).

Nearly all planned clinical sites for Part A of REO 033 have now been activated, and multiple patients are currently enrolled (link to study on ClinicalTrials.gov). With the site activation process largely complete, the Company is focused on accelerating enrollment and generating randomized clinical data evaluating the contribution of pelareorep to the current standard-of-care regimen.

REO 033 is a randomized controlled study evaluating pelareorep in combination with folinic acid, fluorouracil and irinotecan (“FOLFIRI”) and bevacizumab versus FOLFIRI and bevacizumab in patients with second-line RAS-mutant MSS mCRC. Part A is expected to enroll approximately 60 patients randomized between the two treatment arms, with objective response rate (“ORR”) as the primary endpoint, and progression-free survival (“PFS”), overall survival (“OS”), safety, and biomarker analyses among the additional endpoints.

“We are seeing strong momentum in REO 033 now that substantially all of our planned sites are open and multiple patients are on study,” said John McAdory, Chief Operating Officer of Oncolytics. “Given the current pace of enrollment, we expect to have the ability to report interim data from Part A by year-end, based on the number of evaluable patients enrolled by the end of October. Importantly, with site activation substantially behind us, our focus is now squarely on enrollment, execution, and generating the randomized clinical data that can inform the next stage of the program.”

REO 033 Builds on Encouraging REO 022 Clinical Data

REO 033 was designed to prospectively evaluate the efficacy signals previously observed in REO 022 in a randomized setting. In REO 022, pelareorep in combination with FOLFIRI and bevacizumab demonstrated encouraging ORR, PFS, and OS compared with historical second-line benchmarks:

Efficacy Measure	REO 022: Pelareorep + FOLFIRI + Bevacizumab1	Historical Second-Line Benchmark
Objective Response Rate	33%	~6–11%2, 3
Median Progression-Free Survival	16.6 months	~5.7 months2
Median Overall Survival	27.0 months	~11.2 months2
Median Duration of Response	19.5 months	~4–6 months4

The REO 022 results were generated in a small, non-randomized study, and cross-study comparisons have inherent limitations. REO 033 is designed to test the pelareorep regimen prospectively against a concurrent control arm and determine whether the efficacy signals observed in REO 022 can be replicated in a randomized study.

Potential Registration Path Aligned with the Food and Drug Administration

The Company recently aligned with the U.S. Food and Drug Administration (the “FDA”) on the concept for a potential pivotal Part B expansion of REO 033.

Under the proposed regulatory strategy, Part B would build directly upon the ongoing randomized REO 033 study and could support a potential accelerated approval submission based on objective response rate, with progression-free survival providing the basis for potential full approval.

The Company expects data from Part A to inform the final size and execution of the potential pivotal Part B expansion.

About Pelareorep
Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. It has been administered to over 1,200 patients, and clinical studies have demonstrated pelareorep’s potential to enhance the activity of checkpoint inhibitors and other anti-cancer therapies across multiple solid tumor types.

About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically inactive tumors to active through the activation of innate and adaptive immune responses.

The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal, anal, and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics.

References

1. Goel S, et al. Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer. Mol Cancer Ther. 2020 May;19(5):1148-1156. doi: 10.1158/1535-7163.MCT-19-1117.
2. Bennouna J. Lancet Oncol (14):29-37, 2013
3. Iwamoto S. Ann Oncol. Jul;26(7):1427-33, 2015
4. FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C–mutated colorectal cancer. Published June 21, 2024. Accessed April 28, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer

Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include those regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the Company’s goals, strategies, and objectives; expectations around the design, milestones, anticipated timelines and expected outcomes for current and future studies; the timeline and outcome of interim data from Part A of REO 033; the results of the proposed regulatory strategy and approval of Part B of REO 033; the Company’s belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; and the Company’s goals and expectations for its potential registrational development path for pelareorep in multiple gastrointestinal cancers. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.

Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.com

AS Inbank has decided to prematurely redeem the Additional Tier 1 bonds issued on 1 November 2021, registered under ISIN code EE3300002286 (hereafter: Inbank AT1 Bonds).

The early redemption will be carried out in accordance with the terms and conditions of the Inbank AT1 Bonds, which permit full or partial early redemption after 1 November 2026, provided that investors are notified at least 30 days in advance and with the prior consent of the Estonian Financial Supervision and Resolution Authority. By its Management Board resolution dated 31 August 2026, the Estonian Financial Supervision and Resolution Authority has given its consent to the redemption. 

Inbank will prematurely redeem all 450 Inbank AT1 Bonds, each with a nominal value of €10,000 and a total nominal value of €4,500,000. Bondholders will receive the full nominal value of their bonds together with accrued and unpaid interest up to the redemption date. The total amount payable per bond will be €10,070.83.

The redemption payment date will be on 2 November 2026. The list of bondholders will be fixed on 30 October 2026, at the end of the business day of the Nasdaq CSD settlement system (the record date). 

Inbank is a financial technology company with an EU banking license that connects merchants, consumers and financial institutions on its next generation embedded finance platform. Partnering with more than 6,200 merchants, Inbank has 807,000+ active contracts and collects deposits across 7 markets in Europe. Inbank bonds are listed on the Nasdaq Tallinn Stock Exchange.

Additional information:
Styv Solovjov
AS Inbank
Head of Investor Relations
+372 5645 9738
styv.solovjov@inbank.ee